Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | UGCG | Q16739 | 1/20 | 0.40 |
| ▸ | CTSG | P08311 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19967154 | 0.81 | DHPS (0.52) | CYP11B2CYP11B1RAB9AFFAR4LMNA | |
| SCHEMBL1721253 | 0.80 | FFAR4 (0.60) | CYP11B2CYP11B1FFAR4LMNATDP1 | |
| SCHEMBL1721366 | 0.78 | FFAR4 (0.68) | CYP11B2CYP11B1NPC1RAB9AFFAR4 | |
| SCHEMBL29985044 | 0.75 | UGCG (0.43) | CYP11B2CYP11B1NPC1RAB9AFFAR4 | |
| SCHEMBL1726319 | 0.74 | CYP11B2 (0.58) | CYP11B2CYP11B1NPC1RAB9AFFAR4 | |
| SCHEMBL19965013 | 0.74 | CYP11B2 (0.43) | CYP11B2CYP11B1NPC1RAB9APKM | |
| SCHEMBL26322957 | 0.74 | CYP11B2 (0.46) | CYP11B2CYP11B1NPC1RAB9AFFAR4 | |
| SCHEMBL19967332 | 0.74 | FFAR4 (0.64) | CYP11B2CYP11B1FFAR4LMNATDP1 | |
| SCHEMBL28632326 | 0.74 | NPC1 (0.73) | CYP11B2NPC1RAB9ALMNATDP1 | |
| SCHEMBL14991663 | 0.74 | CYP11B2 (1.00) | CYP11B2CYP11B1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3509588-B1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | INTEGRAL HEALTH INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210347768-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | VALO HEALTH, INC. | 2021-11-11 | — | — | US | disclosed |
| US-10865201-B2 | Bicyclic compounds useful as GPR120 modulators | VALO HEALTH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20190218208-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | VALO HEALTH, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2018049328-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | NUMERATE, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865201-B2 | Bicyclic compounds useful as GPR120 modulators | GPR119, GPR180, GPR65 | CYP11B2 489/4885CYP11B1 524/4885NPC1 347/4885 |
| US-20190218208-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 489/4885CYP11B1 524/4885NPC1 347/4885 |
| US-20210347768-A1 | BICYCLIC COMPOUNDS USEFUL AS GPR120 MODULATORS | GPR119, GPR180, GPR65 | CYP11B2 489/4885CYP11B1 524/4885NPC1 347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.